Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/linnaeus-therapeutics-announces-issuance-of-composition-of-matter-patent-for-lns8801-by-the-european-patent-office-302105941.html
https://www.prnewswire.com/news-releases/linnaeus-therapeutics-announces-presentation-of-positive-clinical-data-of-lns8801-in-metastatic-uveal-melanoma-at-2023-asco-annual-meeting-301843582.html
https://www.prnewswire.com/news-releases/linnaeus-therapeutics-granted-orphan-drug-designation-for-lns8801-for-the-treatment-of-patients-with-metastatic-cutaneous-melanoma-301725268.html
https://www.prnewswire.com/news-releases/linnaeus-therapeutics-announces-issuance-of-patent-for-lns8801-by-the-us-patent-and-trademark-office-301629751.html
https://www.prnewswire.com/news-releases/linnaeus-therapeutics-announces-presentation-of-lns8801-clinical-data-at-2022-esmo-annual-meeting-301621714.html
https://www.prnewswire.com/news-releases/linnaeus-therapeutics-announces-presentation-of-positive-clinical-data-of-lns8801-at-2022-asco-annual-meeting-301561693.html
https://www.prnewswire.com/news-releases/linnaeus-therapeutics-announces-presentation-of-pre-clinical-data-of-lns8801-at-2022-aacr-annual-meeting-301523312.html
https://www.prnewswire.com/news-releases/linnaeus-therapeutics-granted-orphan-drug-designation-for-lns8801-for-the-treatment-of-patients-with-metastatic-uveal-melanoma-301244458.html
https://www.prnewswire.com/news-releases/linnaeus-therapeutics-granted-orphan-drug-designation-for-lns8801-for-the-treatment-of-patients-with-metastatic-uveal-melanoma-301244458.html
https://www.prnewswire.com/news-releases/linnaeus-therapeutics-announces-issuance-of-composition-of-matter-patent-for-lns8801-by-the-us-patent-and-trademark-office-301239124.html